Lexaria Bioscience Files Definitive Proxy Statement
Ticker: LEXX · Form: DEF 14A · Filed: Nov 27, 2024
Sentiment: neutral
Topics: proxy-statement, annual-meeting, regulatory-filing
TL;DR
Lexaria Bioscience filed its proxy statement for the Jan 14, 2025 meeting. Shareholders vote soon.
AI Summary
Lexaria Bioscience Corp. filed a definitive proxy statement (DEF 14A) on November 27, 2024, for its annual meeting on January 14, 2025. The company, incorporated in Nevada with its fiscal year ending August 31, is seeking shareholder approval for various corporate matters. The filing indicates no fee was required for this submission.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda and proposals for the upcoming annual meeting, allowing them to make informed voting decisions on the company's future direction.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.
Key Numbers
- 20250114 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20241127 — Filing Date (Date the definitive proxy statement was filed with the SEC.)
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Registrant
- 0001348362 (company) — Central Index Key
- 20250114 (date) — Annual Meeting Date
- 20241127 (date) — Filing Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes on important corporate matters, such as the election of directors or approval of executive compensation, typically in advance of an annual or special meeting.
When is the Lexaria Bioscience Corp. annual meeting?
The annual meeting for Lexaria Bioscience Corp. is scheduled for January 14, 2025.
What is Lexaria Bioscience Corp.'s fiscal year end?
Lexaria Bioscience Corp.'s fiscal year ends on August 31.
Where is Lexaria Bioscience Corp. incorporated?
Lexaria Bioscience Corp. is incorporated in Nevada (NV).
Was there a filing fee for this DEF 14A?
No, the filing indicates that no fee was required for this DEF 14A filing.
Filing Stats: 4,868 words · 19 min read · ~16 pages · Grade level 13.2 · Accepted 2024-11-27 14:39:04
Key Financial Figures
- $3.06 — of common stock at an exercise price of $3.06 per share and up to 57,190 shares of co
- $3.825 — of common stock at an exercise price of $3.825 per share, to an institutional investor
Filing Documents
- lxrp_def14a.htm (DEF 14A) — 545KB
- lxrp_def14aimg15.jpg (GRAPHIC) — 6KB
- lxrp_def14aimg16.jpg (GRAPHIC) — 1KB
- lxrp_def14aimg17.jpg (GRAPHIC) — 1KB
- lxrp_def14aimg18.jpg (GRAPHIC) — 1KB
- lxrp_def14aimg3.jpg (GRAPHIC) — 211KB
- lxrp_def14aimg4.jpg (GRAPHIC) — 20KB
- lxrp_pre14aimg2.jpg (GRAPHIC) — 10KB
- 0001640334-24-001798.txt ( ) — 894KB
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management 5 DIRECTOR NOMINEES 7 Board Diversity 7 Business Experience 8 Executive Officers 10 Family Relationships 11 Involvement in Certain Legal Proceedings 11 Corporate Governance 12 Committees of the Board of Directors 14 AUDIT AND FINANCE COMMITTEE REPORT 15 Director Independence 15 Shareholder Communications with Our Board of Directors 15 Board Leadership Structure 16 Risk Oversight 16 Section 16(a) Beneficial Ownership Reporting Compliance 16
Executive Compensation
Executive Compensation 16 Compensation Discussion and Analysis 19 Compensation Plans 22 Other Forms of Compensation 23 Pay vs Performance 24 Compensation of Directors 25 Securities Authorized for Issuance under Equity Compensation Plans 26 Transactions with Related Persons and Related Person Transaction Policy 26 Anti-Hedging Policy 26 Employment Agreements 26 Fees Paid to Our Independent Registered Public Accounting Firm 27 i PROPOSALS FOR SHAREHOLDER VOTE 28 Proposal 1 Election of Directors 28 Proposal 2 Ratification of the Continued Appointment of the Independent Registered Public Accounting Firm 28 Proposal 3 Non-Binding, Advisory Approval of Compensation of Our Named Executive Officers; 29 Proposal 4 Non-Binding, Advisory Approval of Frequency of Future Advisory on Named Executive Officer Compensation 30 Proposal 5 Approval of the Warrant Exercise Proposal 31 Proposal 6 Ratification and Approval of Acts of the Directors 33 INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON 33 "HOUSEHOLDING" OF PROXY MATERIALS 33 SHAREHOLDER PROPOSALS 33 WHERE YOU CAN FIND MORE INFORMATION 34 SOLICITATION OF PROXIES 34 OTHER MATTERS 34 ii LEXARIA BIOSCIENCE CORP. 100 – 740 McCurdy Road Kelowna, BC, Canada V1X 2P7 Telephone: (250) 765-6424 PROXY STATEMENT ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 14, 2025 GENERAL INFORMATION ABOUT THE MEETING OF SHAREHOLDERS The Board of Directors of Lexaria Bioscience Corp. (" Lexaria ", " we ", " us " or " our ") is soliciting proxies for use at the Annual and Special Meeting of Shareholders to be held via Event Conferencing by way of calling: for Toronto residents (416) 764-8658 ; and for all others 1-888-886-7786 , at 1:00 p.m. (PT), on Tuesday, January 14, 2025 or at any adjournment of the Annual and Special Meeting (the " Meeting "). This proxy statement, the attached notice of the Meeting, a proxy card and our Annual Report on